NAD and Breast Cancer: Implications for Tumor Growth

Breast tumors depend on a steady supply of nicotinamide adenine dinucleotide, better known as NAD+, to fuel their growth, repair their DNA, and evade immune detection. This small molecule, present in every living cell, acts as a metabolic currency that cancer cells spend far more aggressively than healthy tissue. What makes the NAD–breast cancer connection so difficult to exploit therapeutically is that the same molecule supports both tumor-promoting and tumor-suppressing processes, sometimes through the very same enzyme depending on the stage and subtype of the disease.

Why Breast Tumors Need So Much NAD

Healthy cells burn glucose in a measured way, extracting energy through a long chain of reactions that depends on NAD+ shuttling electrons at multiple steps. Breast cancer cells, like most solid tumors, shift much of their glucose processing toward a faster, less efficient route called aerobic glycolysis. In this setup, glucose is rapidly broken down to pyruvate, which is then converted to lactate. That last conversion is critical because it regenerates oxidized NAD+ from NADH, essentially recycling the molecule so glycolysis can keep running at high speed.¹ The enzyme responsible for this recycling step, lactate dehydrogenase A, is consistently overproduced in breast cancers and other neoplastic tissues, ensuring rapid ATP generation and a constantly replenished NAD+ pool.²

This metabolic rewiring does more than just keep the lights on. NAD+ also serves as a raw material for enzymes that silence genes, repair broken DNA, and send signals between cells. By maintaining abnormally high NAD+ turnover, breast tumors gain access to all of these processes simultaneously. One NAD-linked transcriptional regulator, CtBP2, has even been described as a cellular “NADH sensor” that can connect the metabolic state of a cell directly to changes in which genes get turned on or off, linking energy metabolism to the epigenetic reprogramming that drives cancer progression.¹

NAMPT, the Gatekeeping Enzyme

Most of the NAD+ in a cancer cell does not come from dietary sources. Instead, it is recycled internally through a “salvage pathway” that rebuilds NAD+ from nicotinamide, a breakdown product. The bottleneck enzyme in that pathway is called NAMPT (nicotinamide phosphoribosyltransferase), and it has become one of the most studied targets in breast cancer metabolism. Blocking NAMPT slashes intracellular NAD+ levels, which in turn starves the enzymes that depend on it.

But NAMPT’s role in breast cancer is not as straightforward as “more enzyme equals more tumor.” In one set of experiments, researchers found that knocking down NAMPT in breast cancer cells actually enhanced their metastatic aggressiveness, partly by altering the expression and function of integrins, the surface proteins that help cells grip their surroundings and migrate.³ In other words, reducing NAD+ supply may slow a tumor’s ability to grow in place while accidentally making its surviving cells more dangerous. This kind of paradox runs throughout NAD biology in cancer and is one reason why simply cutting off the NAD+ supply has not translated into a simple cure.

A separate line of research tells a different story about NAMPT and triple-negative breast cancer. Metabolomic analysis using labeled glucose showed that blocking NAMPT in these cells produced roughly a 30 to 47 percent drop in intracellular NAD+ levels, accompanied by a collapse in glycolytic output and changes in other key metabolic intermediates.⁴ The context matters: the same enzyme can play very different roles depending on the breast cancer subtype and the stage of disease.

The Tryptophan Route and Immune Escape

The salvage pathway is not the only way cells make NAD+. A second, less discussed route starts with the amino acid tryptophan and proceeds through what is known as the kynurenine pathway. This pathway has drawn attention in breast cancer research not just as a NAD+ source but as a mechanism of immune suppression. The first enzyme in the chain, IDO1, breaks down tryptophan and has been found at elevated levels in advanced breast cancer patients, where it correlates with poor prognosis.⁵

The immune connection works in two ways. First, tryptophan depletion itself can starve nearby T cells that need the amino acid to function. Second, the kynurenine metabolites generated along the pathway actively promote the expansion of immunosuppressive regulatory T cells. In clinical data from two large microarray databases, the overwhelming majority of invasive breast cancer patients showed altered expression of kynurenine pathway enzymes compared to normal tissue.⁵ So this alternative NAD-producing route does double duty for tumors: it generates NAD+ and simultaneously cripples the immune response.

NAD-Dependent Enzymes With Dual Loyalties

Once made, NAD+ feeds into enzymes that can either help or hinder tumors depending on the setting. Two families stand out in breast cancer: sirtuins and PARPs.

Sirtuins are a family of NAD+-dependent enzymes that remove chemical tags from proteins, influencing everything from gene expression to stress resistance. Despite sharing a high degree of structural similarity, different sirtuin family members can act as either tumor promoters or tumor suppressors depending on the cancer type.⁶ SIRT1, the best-studied member, illustrates the problem perfectly. In early-stage breast cancer, it appears to protect against tumor formation by helping maintain genomic stability. But in aggressive subtypes like triple-negative breast cancer, the same enzyme promotes the transition of cells from a stationary state to a mobile, invasive one, drives metastasis, and contributes to resistance against chemotherapy.⁷ Targeting SIRT1 in breast cancer therefore depends entirely on knowing the disease stage and molecular subtype you are dealing with.

PARPs, particularly PARP1, are DNA repair enzymes that consume NAD+ while fixing single-strand breaks in DNA. When DNA damage is severe, PARP activity ramps up and can significantly deplete a cell’s NAD+ stores. In experiments with a breast cancer cell line exposed to a DNA-damaging agent, PARP activation led to a substantial drop in NAD+ levels, and treating those cells with a PARP inhibitor restored NAD+ concentrations.⁸ This relationship between PARP activity and NAD+ availability has become central to how PARP inhibitor drugs work in breast cancer treatment, as discussed below.

How NAD Metabolism Helps Tumors Hide From the Immune System

Beyond fueling growth and DNA repair, NAD+ metabolism actively shapes the immune environment around breast tumors. Researchers have found that NAMPT drives the expression of PD-L1, a surface protein that tells attacking T cells to stand down. Specifically, NAMPT was shown to be necessary for the ability of interferon-gamma to induce PD-L1 expression across multiple tumor types, enabling immune evasion in a way that depends on CD8+ T cells.⁹

NAMPT also exists in a secreted, extracellular form called eNAMPT, which acts almost like a signaling molecule in the tumor’s neighborhood. Neutralizing eNAMPT in breast cancer models reactivated anti-tumor immune responses by switching on CD8+ T cells that produce interferon-gamma and granzyme B, the molecules killer T cells use to destroy their targets. At the same time, eNAMPT neutralization reduced the suppressive behavior of regulatory T cells, the immune cells that normally dial down attacks.¹⁰

Another NAD-linked molecule with immune implications is CD38, an enzyme that degrades NAD+ and was found to be the most enriched protein in a particularly dangerous type of breast tumor cell that sits between epithelial and mesenchymal states, a so-called “hybrid” cell thought to drive metastasis. In these hybrid tumors, the NAD signaling pathway was the most upregulated among several identified pathways, alongside p53, VEGF, and interleukin signaling.¹¹ High CD38 expression in the tumor microenvironment can deplete local NAD+, paradoxically starving nearby immune cells while the tumor cells themselves upregulate their own biosynthetic machinery to compensate. NAD-degrading enzymes, broadly called NADases, are now recognized as key contributors to the immunosuppressive microenvironment in breast tumors.¹²

Triple-Negative Breast Cancer and the NAMPT Vulnerability

Triple-negative breast cancer (TNBC), defined by the absence of estrogen receptor, progesterone receptor, and HER2 expression, has fewer targeted therapy options than other subtypes. This has made its metabolic dependencies attractive targets. TNBC cells appear to be particularly reliant on the NAMPT-driven NAD+ supply for glycolysis and proliferation. Researchers identified NAMPT as a central metabolic node connecting integrin signaling, which governs how cells interact with their surroundings, to NAD+ biosynthesis and glycolytic flux. When both focal adhesion kinase (FAK, a downstream integrin signal) and NAMPT were inhibited together, tumor growth was suppressed by roughly 80 percent in experimental models.⁴

NAMPT inhibition also sensitizes TNBC cells to PARP inhibitors. In a drug screen designed to find compounds that make the PARP inhibitor olaparib more effective, NAMPT emerged as a key modifier of drug response. Since NAMPT produces the NAD+ that PARP enzymes consume as substrate, cutting the supply leaves PARP unable to repair DNA breaks, amplifying the drug’s effect.¹³ This principle of “synthetic lethality,” where two non-lethal disruptions combine to kill cancer cells, has driven the development of dual-action drugs targeting both PARP and NAMPT simultaneously in BRCA wild-type TNBC, a group that does not respond well to PARP inhibitors alone.¹⁴

Metastasis and the NADP(H) Branch

The NAD story extends beyond NAD+ itself. A related molecule, NADP(H), is made from NAD+ by an enzyme called NADK and plays a distinct role in metastasis. While NAD+ handles electron transfer in energy production and signaling, NADP(H) is the cell’s main defense against oxidative stress, the damaging reactive oxygen species that cells encounter during the process of detaching from a primary tumor, traveling through the bloodstream, and colonizing a distant organ.

Researchers found that NADK is upregulated in metastatic breast cancer cells, enabling them to expand their NADP(H) reserves. This expanded antioxidant capacity allows metastatic cells to survive the oxidative challenges of the metastatic cascade far better than cells with normal NADK levels.¹⁵ Because NADK sits at the branch point between NAD+ and NADP(H), it represents a distinct therapeutic target from NAMPT. Inhibiting NADK would not necessarily disrupt primary tumor growth the way NAMPT inhibition does, but it could specifically impair the ability of breast cancer cells to spread.

Where NAD+ Sits Inside the Cell Matters for Drug Response

An underappreciated wrinkle in this story is that NAD+ levels are not uniform throughout a cell. Mitochondria, the nucleus, and the cytoplasm each maintain their own pools, and the distribution between compartments turns out to affect how breast cancer cells respond to treatment. A transporter protein called SLC25A51 ferries NAD+ into mitochondria. When researchers knocked down this transporter in breast cancer cell lines, NAD+ accumulated in the nucleus instead of the mitochondria, boosting PARP1 activity and enhancing DNA repair in the nuclear compartment.

This had a direct consequence for drug sensitivity. In triple-negative MDA-MB-436 cells, which are normally sensitive to the PARP inhibitor talazoparib, knocking down SLC25A51 clearly increased the drug concentration needed to kill cells. The same pattern held for olaparib in MCF7 and MDA-MB-231 cells, confirming the effect was not limited to a single cell line.¹⁶ The implication is sobering: if a breast tumor happens to express low levels of the mitochondrial NAD+ transporter, its nuclear PARP enzymes have more fuel to work with, and PARP inhibitor drugs become less effective. Total NAD+ in the cell might look normal on a bulk measurement, masking a distribution that undermines therapy.

NAD Biosynthesis Profiles as a Biomarker for Treatment Selection

Given NAD+’s many connections to tumor biology, researchers have begun asking whether a tumor’s overall NAD biosynthetic activity could predict which patients will respond to specific treatments. A study that classified breast cancers into high and low NAD+ biosynthetic subtypes based on enzyme expression found several clinically relevant patterns. Tumors in the high biosynthetic group carried higher tumor mutation burdens, more neoantigens, and greater homologous recombination deficiency. They also expressed more immune checkpoint molecules like PD-L1, PD-1, LAG3, and CTLA-4.¹⁷

That combination, lots of mutations plus lots of checkpoint proteins, is exactly the profile that tends to respond well to immunotherapy drugs like PD-1 or CTLA-4 blockers. Indeed, predicted immunotherapy sensitivity scores were significantly higher in the high NAD+ biosynthetic group.¹⁷ This does not mean high NAD+ biosynthesis is good news overall, since these tumors tend to be more aggressive. But it does suggest that NAD+ metabolic profiling could help oncologists identify which patients are most likely to benefit from checkpoint immunotherapy, a decision that currently relies on a patchwork of other biomarkers.

The mutation landscape also differed between groups. High NAD+ biosynthetic tumors more frequently carried TP53 mutations, while low NAD+ biosynthetic tumors were enriched for PIK3CA mutations, a gene that drives a distinct growth signaling pathway.¹⁷ These associations hint that NAD+ metabolic activity does not just reflect how fast a tumor is burning fuel. It correlates with fundamental differences in the genetic events driving the cancer, which could eventually help refine treatment strategies beyond what current subtyping systems capture.

NAMPT Inhibitors in Early Development

Several small-molecule NAMPT inhibitors have entered preclinical testing, and a handful have reached early clinical trials for various cancers. In breast cancer specifically, compounds following established NAMPT inhibitor designs have shown activity against triple-negative mammary tumors in mouse models.¹⁸ The newer strategy of building dual-function molecules that block both PARP and NAMPT in a single compound is aimed at overcoming the limitation that PARP inhibitors currently work well only in BRCA-mutated cancers. By simultaneously cutting NAD+ supply and trapping PARP on DNA, these dual inhibitors may extend the synthetic lethality principle to BRCA wild-type TNBC patients who currently lack targeted options.¹⁴

A separate therapeutic angle comes from the immune side. Because NAMPT and its secreted form eNAMPT are so deeply involved in PD-L1 expression and T cell suppression, blocking these enzymes could complement existing checkpoint immunotherapies. Neutralizing eNAMPT in breast cancer models restored anti-tumor T cell activity even without adding a checkpoint inhibitor drug.¹⁰ Whether this approach can be safely combined with existing immunotherapies in patients remains an open question, but the preclinical evidence suggests that NAD metabolism could become a lever for making breast tumors more visible to the immune system rather than just metabolically weaker.

1
PubMed Central. Transcriptomics and Metabolomics Integration Reveals Redox-Dependent Metabolic Rewiring in Breast Cancer Cells
2
PLOS ONE. The activation of lactate dehydrogenase induced by mTOR drives neoplastic change in breast epithelial cells
3
PubMed Central. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer
4
PubMed. Crosstalk between integrin signaling and NAD⁺ biosynthetic pathways promotes glycolysis, proliferation, survival, and tumor growth in triple-negative breast cancer
5
PubMed Central. Understanding the role of the kynurenine pathway in human breast cancer immunobiology
6
PubMed Central. The Roles of Sirtuin Family Proteins in Cancer Progression
7
PubMed Central. The Roles of Sirt1 in Breast and Gynecologic Malignancies
8
PubMed Central. Metabolic responses induced by DNA damage and poly (ADP-ribose) polymerase (PARP) inhibition in MCF-7 cells
9
PubMed. NAD(+) Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
10
PubMed Central. Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) neutralization counteracts T cell immune evasion in breast cancer
11
Cancer Research. Accumulation of CD38 in Hybrid Epithelial/Mesenchymal Cells Promotes Immune Remodeling and Metastasis in Breast Cancer
12
PubMed Central. Targeting NAD+ metabolism: dual roles in cancer treatment
13
PubMed Central. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
14
PubMed. Dual PARP/NAMPT Inhibitors for BRCA Wild-Type Triple-Negative Breast Cancer: Disrupting Homologous Recombination Repair and Activating Antitumor Immunity
15
PubMed Central. NADK-mediated de novo NADP(H) synthesis is a metabolic adaptation essential for breast cancer metastasis
16
Nucleic Acids Research. Absence of mitochondrial SLC25A51 enhances PARP1-dependent DNA repair by increasing nuclear NAD+ levels
17
Pathology and Oncology Research. NAD+ biosynthesis metabolism predicts prognosis and indicates immune microenvironment for breast cancer
18
PubMed Central. Recent Advances in NAMPT Inhibitors: A Novel Immunotherapic Strategy